Association between serious immune-related adverse events and survival in patients with advanced HCC treated by nivolumab: A single-center experience.

e16661Background: Nivolumab received accelerated approval by the FDA in 2017 for the treatment of advanced hepatocellular carcinomas (HCC). This study is aimed at evaluating the relationship betwee...